ClinicalTrials.gg

Program

zipalertinib

Also written as “TAS6417” and “CLN-081”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lung Neoplasms · Carcinoma, led by 2 companies.

Furthest: phase 3, since Jul 11, 20234 company-led studies, 4 open or runningNext primary completion: May 27, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka33 open or runningphase 3since Jul 11, 2023Jul 11, 2023May 27, 2027phase 3 · NCT05973773
Cullinan Therapeutics11 open or runningphase 2since Jul 23, 2019Jul 23, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2019First study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Cullinan TherapeuticsCullinan Therapeutics · NCT04036682 · 284 enrolled · United States, Hong Kong, Italy and more
  2. Jul 11, 2023Otsuka's first study: phase 3 study in Lung DiseasesNew to OtsukaOtsuka · NCT05973773 · 285 enrolled · United States, Belgium, Brazil and more
  3. Jul 11, 2023Phase 2 study in CarcinomaOtsuka · NCT05967689 · 220 planned · United States, Australia, Canada and more
  4. Aug 11, 2025Phase 3 study in Lung NeoplasmsOtsuka · NCT07128199 · 360 planned · United States, Argentina, Australia and more

Ahead

  1. May 27, 2027Primary completion: phase 3 study in Lung DiseasesOtsuka · NCT05973773
  2. Aug 31, 2028Primary completion: phase 2 study in CarcinomaOtsuka · NCT05967689
  3. Oct 1, 2029Primary completion: phase 3 study in Lung NeoplasmsOtsuka · NCT07128199

TargetBeta

EGFR →read by rule
“An orally available selective inhibitor of a broad spectrum of epidermal growth factor receptor (EGFR) mutations, including EGFR exon 20 insertion mutations (EGFR Ex20ins; Ex20ins mutations), ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
befotertinibruleBetta Pharmaceuticalsphase 36
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07128199Lung Neoplasms · United States, Argentina, Australia and more3RecruitingOtsukaOct 1, 2029360
NCT05973773Lung Diseases · United States, Belgium, Brazil and more3Active, not recruitingOtsukaMay 27, 2027285
NCT05967689Carcinoma · United States, Australia, Canada and more2RecruitingOtsukaAug 31, 2028220
NCT04036682Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Italy and more2Active, not recruitingCullinan TherapeuticsOct 13, 2025284

How it is read

Names in the registry

  • “TAS6417”, 3 entries
  • “CLN-081”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.